PHATHOM PHARMACEUTICALS, INC. (PHAT) Current Ratio
- Current ratio · latest quarter: Value 1.92×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.92× | Current assets / current liabilities. $295.92M ÷ $153.78M ≈ 1.92× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 295.92M USD | Assets, Current |
| Current obligations | 153.78M USD | Liabilities, Current |
| Cash and equivalents | 182.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | 7.71M USD | Inventory, Net |
| Payables | 5.36M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $295.92M | $153.78M | $182.48M | (m) | (m) | $7.71M | $5.36M | $0.00 | 1.92× |
| 2026-03-31 | $276.57M | $125.04M | $180.90M | (m) | (m) | $6.51M | $6.37M | $0.00 | 2.21× |
| 2025-12-31 | $228.97M | $132.04M | $129.97M | (m) | (m) | $5.52M | $4.98M | $0.00 | 1.73× |
| 2025-09-30 | $207.78M | $93.12M | $135.16M | (m) | (m) | $3.61M | $1.07M | $0.00 | 2.23× |
| 2025-06-30 | $218.88M | $91.82M | $149.57M | (m) | (m) | $3.43M | $4.01M | $0.00 | 2.38× |
| 2025-03-31 | $264.90M | $74.03M | $212.31M | (m) | (m) | $3.17M | $11.62M | $0.00 | 3.58× |
| 2024-12-31 | $360.13M | $85.73M | $297.26M | (m) | (m) | $3.21M | $10.51M | $0.00 | 4.20× |
| 2024-09-30 | $373.82M | $65.29M | $334.68M | (m) | (m) | $3.11M | $7.13M | $0.00 | 5.73× |
| 2024-06-30 | $304.79M | $47.01M | $276.24M | (m) | (m) | $2.18M | $7.66M | $0.00 | 6.48× |
| 2024-03-31 | $340.31M | $43.46M | $322.23M | (m) | (m) | $1.46M | $8.40M | $0.00 | 7.83× |
| 2023-12-31 | $397.43M | $38.78M | $381.39M | (m) | (m) | $1.21M | $12.60M | $0.00 | 10.25× |
| 2023-09-30 | $226.73M | $23.98M | $213.68M | (m) | (m) | $111.00K | $5.79M | (m) | 9.46× |
| 2023-06-30 | $257.72M | $21.55M | $248.85M | (m) | (m) | $111.00K | $4.17M | (m) | 11.96× |
| 2023-03-31 | $139.84M | $14.44M | $129.57M | (m) | (m) | (m) | $4.80M | (m) | 9.68× |
| 2022-12-31 | $160.51M | $26.24M | $155.38M | (m) | (m) | $0.00 | $10.00M | $0.00 | 6.12× |
| 2022-09-30 | $197.81M | $22.88M | $196.84M | (m) | (m) | (m) | $7.13M | (m) | 8.65× |
| 2022-06-30 | $209.26M | $21.07M | $207.39M | (m) | (m) | (m) | $5.76M | (m) | 9.93× |
| 2022-03-31 | $145.74M | $11.39M | $138.09M | (m) | (m) | (m) | $2.86M | (m) | 12.79× |
| 2021-12-31 | $186.53M | $18.92M | $183.26M | (m) | (m) | (m) | $5.15M | (m) | 9.86× |
| 2021-09-30 | $225.31M | $27.81M | $224.62M | (m) | (m) | (m) | $5.58M | (m) | 8.10× |
| 2021-06-30 | $211.34M | $39.61M | $209.67M | (m) | (m) | (m) | $5.40M | $10.35M | 5.34× |
| 2021-03-31 | $242.81M | $40.84M | $237.97M | (m) | (m) | (m) | $10.86M | $11.77M | 5.94× |
| 2020-12-31 | $291.37M | $55.52M | $287.50M | (m) | (m) | (m) | $16.78M | $7.35M | 5.25× |
| 2020-09-30 | $227.16M | $27.67M | $226.36M | (m) | (m) | (m) | $4.79M | $5.56M | 8.21× |
| 2020-06-30 | $248.68M | $13.26M | $247.27M | (m) | (m) | (m) | $4.89M | $1.39M | 18.76× |
| 2020-03-31 | $261.83M | $4.58M | $256.67M | (m) | (m) | (m) | $1.19M | (m) | 57.22× |
| 2019-12-31 | $255.60M | $3.75M | $243.76M | (m) | (m) | (m) | $699.00K | (m) | 68.20× |
| 2019-09-30 | $77.65M | $207.49M | $74.48M | (m) | (m) | (m) | $439.00K | (m) | 0.37× |
| 2018-12-31 | $902.00K | $2.19M | $879.00K | (m) | (m) | (m) | $55.00K | (m) | 0.41× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |